Methanesulfonyl fluoride

Last updated
Methanesulfonyl fluoride
Methanesulfonyl fluoride.svg
Methanesulfonyl fluoride 3D.PNG
Names
Preferred IUPAC name
Methanesulfonyl fluoride [1]
Other names
Fumette, Mesyl fluoride
Identifiers
3D model (JSmol)
AbbreviationsMSF
ChemSpider
ECHA InfoCard 100.008.358 OOjs UI icon edit-ltr-progressive.svg
EC Number
  • 209-192-2
MeSH methanesulfonyl+fluoride
PubChem CID
RTECS number
UNII
UN number UN3389
  • InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3
    Key: KNWQLFOXPQZGPX-UHFFFAOYSA-N
  • CS(=O)(=O)F
Properties
CH3FO2S
Molar mass 98.09 g·mol−1
Appearanceliquid
Odor pungent
Density 1.427 g/mL [3]
Boiling point 123 to 124 °C (253 to 255 °F; 396 to 397 K) [3]
Reacts
1.360 [2]
Hazards
Occupational safety and health (OHS/OSH):
Main hazards
Corrosive
Highly toxic
GHS labelling:
GHS-pictogram-acid.svg GHS-pictogram-skull.svg
H300, H314, H330
P301+P310, P303+P361+P353, P304+P340, P305+P351+P338, P320, P330, P405, P501
Related compounds
Other anions
Methanesulfonyl chloride
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Methanesulfonyl fluoride (MSF) has long been known to be a potent inhibitor of acetylcholinesterase (AChE), the enzyme that regulates acetylcholine, an important neurotransmitter in both the central and peripheral nervous systems. [4] [5]

Contents

Technical and physical properties

MSF is a clear, colorless to yellowish hygroscopic liquid (attracts and holds water by absorption or adsorption). It is corrosive and highly toxic. It is an oxydiaphoric inhibitor (acid-transferring inhibitor) [6] of the enzyme acetylcholinesterase. [6] [3] MSF, which is a liquid at room temperature, has a vapor pressure of 19.2 mmHg, slightly more volatile than water which has a vapor pressure of 18.8 mmHg at 21 °C. This vapor has an LCt50 (lethal concentration, 50% death rate in a given time) in rats of between 4 and 5 parts per million (ppm) during one hour of exposure or between 1 and 1.2 ppm during 7 hours of exposure. MSF produced no subtle biological effects from direct action of MSF independent of its ability to inhibit cholinesterase. Repeated exposures to 1/10 of the LCt50 did not produce overt systemic toxicity or significant pathology. [7] MSF can also cause severe skin burns and serious eye damage, if contact is made. It is a lachrymator and its vapor causes tears in eyes. [8] [2]

Methanesulfonyl fluoride has a pungent odor. It undergoes decomposition on heating to liberate additional toxic fumes of fluorides and sulfur oxides (SOx). [9]

Synthesis

A typical synthesis is to treat methanesulfonyl chloride with potassium fluoride or potassium bifluoride in water and then steam distill the product out. [10]

Therapeutic study

Animal studies have shown that MSF-induced inhibition of AChE is highly selective for the brain when it is studied in vivo. MSF is an irreversible inhibitor of AChE and its inhibition of AChE is only overcome by de novo synthesis of new AChE in each tissue. The recovery of AChE activity in the brain is less than one-tenth as rapid as AChE recovery in the gastrointestinal system, allowing very high accumulated AChE inhibition in the brain with clinically insignificant AChE inhibition in peripheral tissues. [11] [12] The high selectivity of MSF for inhibition in the brain has suggested that it could be used as a treatment for dementia of the Alzheimer type, [11] that it is effective in reducing the persistent cognitive deficit after stroke, [13] and it is highly effective in reducing normal age-related memory impairment, making aged rats perform as well as younger rats. [14]

Methanesulfonyl fluoride has been tested successfully in three human clinical trials as a treatment for Alzheimer's dementia. Two Phase I clinical trials testing for safety of MSF in humans at the doses proposed for treating dementia have shown that it is well tolerated and relatively free of the side effects of nausea, vomiting, and diarrhea that are produced by the current cholinesterase inhibitors used for the treatment of Alzheimer's dementia. [15] Furthermore, a Phase II, clinical trial testing both the safety and the efficacy of MSF found that it was well tolerated in the aged patients, and it was highly effective in reducing the symptoms of Alzheimer's dementia. [15] US Patent has been issued for the use of MSF for the treatment of dementia. [16]

Related Research Articles

<span class="mw-page-title-main">Soman</span> Chemical compound (nerve agent)

Soman is an extremely toxic chemical substance. It is a nerve agent, interfering with normal functioning of the mammalian nervous system by inhibiting the enzyme cholinesterase. It is an inhibitor of both acetylcholinesterase and butyrylcholinesterase. As a chemical weapon, it is classified as a weapon of mass destruction by the United Nations according to UN Resolution 687. Its production is strictly controlled, and stockpiling is outlawed by the Chemical Weapons Convention of 1993 where it is classified as a Schedule 1 substance. Soman was the third of the so-called G-series nerve agents to be discovered along with GA (tabun), GB (sarin), and GF (cyclosarin).

<span class="mw-page-title-main">Cholinesterase</span> Esterase that lyses choline-based esters

The enzyme cholinesterase (EC 3.1.1.8, choline esterase; systematic name acylcholine acylhydrolase) catalyses the hydrolysis of choline-based esters:

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

<span class="mw-page-title-main">Tacrine</span> Chemical compound

Tacrine is a centrally acting acetylcholinesterase inhibitor and indirect cholinergic agonist (parasympathomimetic). It was the first centrally acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex. Tacrine was first synthesised by Adrien Albert at the University of Sydney in 1949. It also acts as a histamine N-methyltransferase inhibitor.

<span class="mw-page-title-main">Malathion</span> Chemical compound

Malathion is an organophosphate insecticide which acts as an acetylcholinesterase inhibitor. In the USSR, it was known as carbophos, in New Zealand and Australia as maldison and in South Africa as mercaptothion.

<span class="mw-page-title-main">Galantamine</span> Neurological medication

Galantamine is used for the treatment of cognitive decline in mild to moderate Alzheimer's disease and various other memory impairments. It is an alkaloid that has been isolated from the bulbs and flowers of Galanthus nivalis, Galanthus caucasicus, Galanthus woronowii, and some other members of the family Amaryllidaceae, such as Narcissus (daffodil), Leucojum aestivum (snowflake), and Lycoris including Lycoris radiata. It can also be produced synthetically.

<span class="mw-page-title-main">Huperzine A</span> Chemical compound

Huperzine A is a naturally occurring sesquiterpene alkaloid compound found in the firmoss Huperzia serrata and in varying quantities in other food Huperzia species, including H. elmeri, H. carinat, and H. aqualupian. Huperzine A has been investigated as a treatment for neurological conditions such as Alzheimer's disease, but a meta-analysis of those studies concluded that they were of poor methodological quality and the findings should be interpreted with caution. Huperzine A inhibits the breakdown of the neurotransmitter acetylcholine by the enzyme acetylcholinesterase. It is commonly available over the counter as a nutrient supplement, and is marketed as a cognitive enhancer for improving memory and concentration.

<span class="mw-page-title-main">Diisopropyl fluorophosphate</span> Chemical compound

Diisopropyl fluorophosphate (DFP) or Isoflurophate is an oily, colorless liquid with the chemical formula C6H14FO3P. It is used in medicine and as an organophosphorus insecticide. It is stable, but undergoes hydrolysis when subjected to moisture.

<span class="mw-page-title-main">Azinphos-methyl</span> Chemical compound

Azinphos-methyl (Guthion) is a broad spectrum organophosphate insecticide manufactured by Bayer CropScience, Gowan Co., and Makhteshim Agan. Like other pesticides in this class, it owes its insecticidal properties to the fact that it is an acetylcholinesterase inhibitor. It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act, and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.

Ambenonium is a cholinesterase inhibitor used in the management of myasthenia gravis.

<span class="mw-page-title-main">Acetylcholinesterase</span> Primary cholinesterase in the body

Acetylcholinesterase (HGNC symbol ACHE; EC 3.1.1.7; systematic name acetylcholine acetylhydrolase), also known as AChE, AChase or acetylhydrolase, is the primary cholinesterase in the body. It is an enzyme that catalyzes the breakdown of acetylcholine and some other choline esters that function as neurotransmitters:

<span class="mw-page-title-main">Acetylcholinesterase inhibitor</span> Drugs that inhibit acetylcholinesterase

Acetylcholinesterase inhibitors (AChEIs) also often called cholinesterase inhibitors, inhibit the enzyme acetylcholinesterase from breaking down the neurotransmitter acetylcholine into choline and acetate, thereby increasing both the level and duration of action of acetylcholine in the central nervous system, autonomic ganglia and neuromuscular junctions, which are rich in acetylcholine receptors. Acetylcholinesterase inhibitors are one of two types of cholinesterase inhibitors; the other being butyryl-cholinesterase inhibitors. Acetylcholinesterase is the primary member of the cholinesterase enzyme family.

<span class="mw-page-title-main">Cholinesterase inhibitor</span> Chemicals which prevent breakdown of acetylcholine and butyrylcholine

Cholinesterase inhibitors (ChEIs), also known as anti-cholinesterase, are chemicals that prevent the breakdown of the neurotransmitter acetylcholine or butyrylcholine. This increases the amount of the acetylcholine or butyrylcholine in the synaptic cleft that can bind to muscarinic receptors, nicotinic receptors and others. This group of inhibitors is divided into two subgroups, acetylcholinesterase inhibitors (AChEIs) and butyrylcholinesterase inhibitors (BChEIs).

<span class="mw-page-title-main">Ladostigil</span> Chemical compound

Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.

<span class="mw-page-title-main">Rivastigmine</span> Chemical compound

Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

<span class="mw-page-title-main">Cymserine</span> Chemical compound

Cymserine is a drug related to physostigmine, which acts as a reversible cholinesterase inhibitor, with moderate selectivity (15×) for the plasma cholinesterase enzyme butyrylcholinesterase, and relatively weaker inhibition of the better-known acetylcholinesterase enzyme. This gives it a much more specific profile of effects that may be useful for treating Alzheimer's disease without producing side effects such as tremors, lacrimation, and salivation that are seen with the older nonselective cholinesterase inhibitors currently used for this application, such as donepezil. A number of cymserine derivatives have been developed with much greater selectivity for butyrylcholinesterase, and both cymserine and several of its analogues have been tested in animals, and found to increase brain acetylcholine levels and produce nootropic effects, as well as reducing levels of amyloid precursor protein and amyloid beta, which are commonly used biomarkers for the development of Alzheimer's disease.

<span class="mw-page-title-main">Leptophos</span> Chemical compound

Leptophos (O-(4-bromo-2,5-dichlorophenyl) O-methyl phenylphosphonothioate) belongs to the organophosphates and at room temperature it is a stable white solid. It is also known as Phosvel, Abar and Vcs 506. Leptophos was primarily used as a pesticide and fungicide. for rice, cotton, fruit and vegetables until its use was discontinued in 1975 in USA, but still sold in South-Eastern Asia in 1981.

<span class="mw-page-title-main">Ethoprophos</span> Chemical compound

Ethoprophos (or ethoprop) is an organophosphate ester with the formula C8H19O2PS2. It is a clear yellow to colourless liquid that has a characteristic mercaptan-like odour. It is used as an insecticide and nematicide and it is an acetylcholinesterase inhibitor.

<span class="mw-page-title-main">Chelidonine</span> Chemical compound

Chelidonine is an isolate of Papaveraceae with acetylcholinesterase and butyrylcholinesterase inhibitory activity.

<span class="mw-page-title-main">Phenserine</span> Chemical compound

Phenserine is a synthetic drug which has been investigated as a medication to treat Alzheimer's disease (AD), as the drug exhibits neuroprotective and neurotrophic effects.

References

  1. "methanesulfonyl fluoride - Compound Summary (CID 11207)". PubChem. Retrieved July 25, 2012.
  2. 1 2 3 "H53460 Methanesulfonyl fluoride, 98%". Archived from the original on January 16, 2013. Retrieved July 25, 2012.
  3. 1 2 3 "METHANESULFONYL FLUORIDE". chembook. Retrieved July 25, 2012.
  4. Myers, D. K.; Kemp, A. (1954). "Inhibition of Esterases by the Fluorides of Organic Acids". Nature. 173 (4392): 33–4. doi:10.1038/173033a0. PMID   13119739.
  5. Kitz, R; Wilson, IB (1962). "Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase". The Journal of Biological Chemistry. 237: 3245–9. PMID   14033211.
  6. 1 2 Kitz, R; Wilson, IB (1963). "Acceleration of the rate of reaction of methanesulfonyl fluoride and acetylcholinesterase by substituted ammonium ions". The Journal of Biological Chemistry. 238: 745–8 http://www.jbc.org/content/238/2/745.full.pdf#page=1&view=FitH free, automatic full text pdf download, to read offline. PMID   14033210.
  7. Hine, C.H.; Lyons, J.; Eisenlord, G.H.; Wright, J.A.; Long, J.E. (1979). "Three-month inhalation exposure study with methane sulfonylfluoride". American Industrial Hygiene Association Journal. 40 (11): 986–92. doi:10.1080/15298667991430596. PMID   532785.
  8. MSDS, Fisher Scientific
  9. Extremely Hazardous Substances: Superfund Chemical Profiles. William Andrew. 1988. p. 997. ISBN   978-0-8155-1166-3 . Retrieved 25 July 2012.
  10. Gramstad, T.; Haszeldine, R. N. (1956). "33. Perfluoroalkyl derivatives of sulphur. Part IV. Perfluoroalkanesulphonic acids". Journal of the Chemical Society (Resumed): 173–180. doi:10.1039/JR9560000173.
  11. 1 2 Moss, D. E.; Rodriguez, L. A.; Herndon, W. C.; Vincenti, S. P.; Camarena, M. L. (1986). "Sulfonyl Fluorides as Possible Therapeutic Agents in Alzheimer's Disease: Structure/Activity Relationships as CNS Selective Cholinesterase Inhibitors". Alzheimer's and Parkinson's Disease. Advances in Behavioral Biology. Vol. 29. pp. 551–556. doi:10.1007/978-1-4613-2179-8_62. ISBN   978-1-4612-9283-8.
  12. Moss, D.E.; Fariello, Ruggero G.; Sahlmann, Jörg; Sumaya, Isabel; Pericle, Federica; Braglia, Enrico (2012). "A Randomized Phase I Study of Methanesulfonyl Fluoride, an Irreversible Cholinesterase Inhibitor, for the Treatment of Alzheimer's Disease". British Journal of Clinical Pharmacology. 75 (5): 1231–1239. doi:10.1111/bcp.12018. PMC   3635594 . PMID   23116458.
  13. Borlongan, Cesario V.; Sumaya, Isabel C.; Moss, Donald E. (2005). "Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates simple learning and memory deficits in ischemic rats". Brain Research (Submitted manuscript). 1038 (1): 50–8. doi:10.1016/j.brainres.2005.01.028. PMID   15748872.
  14. Malin, David H.; Plotner, Robert E.; Radulescu, Sarah J.; Ferebee, Robert N.; Lake, J.Ronald; Negrete, Pilar G.; Schaefer, Peggy J.; Crothers, Marie K.; Moss, Donald E. (1993). "Chronic methanesulfonyl fluoride enhances one-trial per day reward learning in aged rats". Neurobiology of Aging. 14 (4): 393–5. doi:10.1016/0197-4580(93)90127-W. PMID   8367021.
  15. 1 2 Moss, DE; Berlanga, P; Hagan, MM; Sandoval, H; Ishida, C (1999). "Methanesulfonyl fluoride (MSF): A double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type". Alzheimer Disease and Associated Disorders. 13 (1): 20–5. doi:10.1097/00002093-199903000-00003. PMID   10192638.
  16. US 5798392,Moss; Donald Eugene,"Sulfonyl fluorides for the treatment of Alzheimer's disease",issued 1998-08-25